Body--Internal Uses

{Review of studies}

{Contains useful info, though some statements may need verification} "CDS is chlorine dioxide without sodium chlorite content (NaClO2) in aqueous solution."

"PUNTOS CLAVE: No existe evidencia que respalde la eficacia y seguridad de terapia alternativas como dióxido de cloro, ozonoterapia y agua de..."

(April 2020) "the scientific activity consists in collecting the facts of nature, refraining from collect general theories that "anticipate" them, fleeing from dogmatic systems general, of rhetoric, dialectical subtleties and fantasy, seeking in return the application useful."

[This statement needs refinement: "RESULT: we can breathe the Chlorine Dioxide released by 5. 357 cm3/ d de CDS 0.3% in the room, airing it once a day"] [This statement needs verification: "The distribution dynamics of Chlorine Dioxide in the organism has to be through of blood, which is never separated by more than 20 microns from any cell and the liquid intercell"] [Statement needs validation: "it seems to indicate that in the areas especify where the dissociated Chlorine Dioxide, pI would like to generate a very basic Ph"] [This approach may not be appropriate because correlation actually may be different: "To see the distribution of Chlorine Dioxide, in veins, arteries, kidneys, lungs, etc. radioactive isotope of 35 Cl has been used"] [Graph seems to contradict statement: "maximum that we know empirically, that it is reached after one hour:"] [Rate constant differs significantly in various areas of body, so this statement can't be applied: "Chlorine Dioxide, with a half-life of 1 hour,"] [Graph on page 16 doesn't seem to illustrate patterns described] [How was this determined? "after their biochemical activity they will transform into approximately 0.5 millimoles of sodium chloride"] [How was assumption reached since absorption rate not deduced? "absorption by the vessels blood would transfer Chlorine Dioxide, more quickly", particularly when document says "with the use of CDI there is no discussion that how it enters the circulatory system"?] [Actually, amount safe to inhale differs from amount safe to ingest, since absorption routes and rates are different "usual daily dose of 30 mg...evaporating... throughout a day"] [Current US EPA standards specify acute oral LD50 (which applies for a single day & may not for consecutive days} to be 292 mg/kg. This conflicts with "six hundredth part, at day, from LD 50, which would be taking 30 mg / day"] [Incorrect: "after 2 hours, it has been eliminated from the body." See study 'Metabolism & Pharmacokinetics of Alternate Drinking Water Disinfectants,' 1982] ["10 ml of CDS would provide 10 ml of extra molecular oxygen." However, 2015 'First case of methemoglovinemia caused by a ClO2-based housefold product' reported effect of profound hypoxia]

A Study of WF 10 IV Solution in Patients With Advanced HIV Disease - Full Text View.

**** "This study demonstrates that heme peroxidases from different superfamilies react differently with chlorite. In contrast to plant peroxidases..." "Data about potential chlorite actions under pathological conditions like cardiovascular diseases, where MPO is known for their adverse effects [54], [55], are lacking. In therapeutic use, other possible chlorite effects are modulation and stimulation of immune responses [56], activation of macrophage functions [40], the stimulation of killer cell cytotoxicity [57], methemoglobin formation [44] and formation of chlorine dioxide. The later species has strong anti-microbial properties [58] and can be also derived from one-electron oxidation of chlorite by Compounds I and II of MPO or LPO. At inflammatory sites, the likelihood for the aforementioned chlorite activity might be increased considering enhanced levels of hydrogen peroxide at these sites. Taken together, chlorite can principally cause a number of divergent effects upon its application."

Tetrachlorodecaoxide Systematic (IUPAC) name Molecular oxygen tetrachlorite hydrate Identifiers CAS number 92047-76-2 ATC. "WF 10 [Immunokine™, Macrokine™] is a 1 : 10 dilution of tetrachlorodecaoxide (TCDO) formulated for intravenous injection."

Method of treating hyperglycemia induced Red Blood Cell Disease/Dysfunction (RBCD) caused by generation of early and late glycation end products. Method of treating hemolytic anemia, smoldering hemolytic anemia, sickle cell anemia, hemorrhagic diseases, hemorrhagic stroke, hemorrhagic bleeding. Method of treating RBCD to prevent progression to diabetes associated vascular complications referred to as Syndrome X, particularly to prevent progression to chronic kidney disease, coronary vascular disease, and peripheral vascular disease.

The present invention provides a method of treating or inhibiting at least one of allergic asthma, allergic rhinitis and atopic dermatitis, or of reducing, inhibiting or treating allergy like symptoms

****!!!!******** "While a wide range of oral sodium chlorite regi-mens have been used, the most popular are between 0.75 and 1.5 mg/kg given over 2 – 7 days in a row, followed by a rest period of 7 – 16 days, then repeat-ing (17,25,26). Importantly, it has never been shown that oral sodium chlorite can be absorbed at levels that affect human macrophage function. In rats given radiolabeled chlorite, 34% of the initial dose can be found excreted in the urine over the next 72 h (27). However, in monkeys, chlorite is neutralized in saliva within 1 min and by gastric fl uid in vivo in 5 min (28). Keuhne, one of the world ’ s experts on WF10, states that he studied oral WF10 and found that it “ can act on these mechanisms only intravenously, not orally ” (29). Furthermore, there are data that raise concerns about the safety of oral sodium chlo-rite. According to McGrath and Keuhne, sodium chlorite is converted under acidic conditions (such as those in the stomach) to chlorine dioxide, which can be poisonous (12,29). While a small, short- duration study failed to show evidence of oral chlo-rite toxicity in humans (30), Keuhne stopped his research on oral WF10 “ after two patients collapsed and one nearly died ” while taking it (29)"

"These results indicate that WF10 administration appears safe, may enhance immunologic function, and unlike other macrophage-activating cytokines does not increase HIV expression in this patient population. Further studies of WF10 in larger patient populations are warranted."

{Includes reference to "Kahn J. A single center, phase II study evaluating the effects of WF10 (TCDO) on the kinetics of red blood cell survival, selected immunologic markers of HIV disease, macrophage activation, and the rate of change of viral kinetics. Study report for protocol WF10-96-US-003. Submitted to the US FDA, Report vol. I; 1998, 24 April."

"Substances which stimulate tissue regeneration might be an attractive alternative to prevent progression of subclinical radiation injury to gross tissue failure. Since tetrachlorodecaoxygen anion complex (TCDO) has been described to have such properties "

including Tetrachlorodecaoxide (TCDO) and WF10. "This study demonstrated that WF10 at a dose of 0.5 ml/kg was associated with a sustained immunological response, i.e., sustained elevation of CD8+ T cell numbers, consistent with the proposed mechanism of action. Furthermore, a single-center, phase I/II study, was conducted in 1997 to evaluate safety and the effects of WF10" "After interaction with heme proteins, the chlorite matrix of WF10 acquires oxidizing and chlorinating properties. It has been suggested that WF10 exerts potent immunomodulatory effects most likely through generating physiologic oxidative compounds namely chloramines. Chloramines have been reported to exert cell-protective and anti-inflammatory activities. [0082] Pro-oxidative substances can also have a direct effect on transcriptional activities of the NFAT species of transcription factors."

"Treating a macrophage related disease comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The present invention also provides a method of modulating macrophage accumulation or activation comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The oxidative agent can be chlorite or a chlorite containing..."

"NP001, a pH-adjusted IV formulation of purified Sodium Chlorite, is a novel moleculethat regulates inflammation in vitro andin vivo. Within monocytes/ macrophages, chlorite is converted into taurine chloraminethat downregulates nuclear factorkB(NF-kB) expression and inhibits production of proinflammatory cytokine IL-1b. These mechanisms of downregulation trans-form inflammatory monocytes/macrophagesfrom a proinflammatory to a basal phagocyticstate." "NP001 was generally safe and well-tolerated, except for infusion site pain anddizziness. No significant slowing of decline in the primary or secondary measures was observed.However, slowing of progression was observed in the high-dose group inpatients with greaterinflammation (wide range C-reactive protein). Moreover, NP001 may have dose dependently halted symptom progression in a subset of patients. More than 2 times as many patients on high-dose NP001 (25%) did not progress during 6 months of treatment compared with thoseon placebo (11%). Most “responders”had an elevated biomarker of inflammation, interleukin-18,and were positive for lipopolysaccharide at baseline, which decreased after treatment with NP001."

"The drug substance WF10 inhibited the activation of LPS/IFNγ-stimulated humanmonocyte-derived macrophages. Among them are the diminished expression ofproinflammatory surface markers, the inhibition of the expression of the hyaluronanreceptor CD44, and the binding of hyaluronan to CD44. Further, the overall amountof sulphated proteoglycans and glycosaminoglycans was down-regulated by WF10.These in vitro experiments indicate that WF10 is able to inhibit the proinflammatory activation of macrophages. The results suggested that chlorite is the active principle inWF10 as chlorite caused principally the same changes in targets as WF10. The WF10 component chlorate inhibited only the overall sulphation level of proteoglycans and glycosaminoglycans and the binding of hyaluronan to CD44."

"The invention features methods of treating a macrophage-associated neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), or multiple sclerosis (MS) in a subject by administering chlorite in an amount effective to decrease blood immune cell activation." "WF10, which comprises chlorite (e.g., in the form of tetrachlorodecaoxygen (TCDO)) as its active ingredient"

¿Sirve este químico para tratar el COVID-19? Contactamos al Dr. Fernando Liendo, presidente del grupo Alcos.

** {Incomplete perspective: "Chlorine Dioxide in contact with the air becomes inactivated and becomes two gases Chlorine and Oxygen, so it has no disinfectant properties, and could not serve to disinfect the air we breathe." Actually, under appropriate conditions, chlorine dioxide can be used very powerfully for disinfecting air, because dissociation is only gradual.} {Article has some other inaccuracies, along with many correct important points.}

{Clinic trial of COVID-19 treatment by oral consumption of Chlorine Dioxide}

{Useful links}

The invention features methods of treating a macrophage-associated neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), or multiple sclerosis (MS) in a subject by administering chlorite in an amount effective to decrease blood immune cell activation. The invention also features methods of monitoring therapy by assessing blood immune cell activation before and after therapy.

{WF-10 and NP001} "... contributes to the self-limiting nature of inflammation. Sodium chlorite (NaClO2; in solution with 63 mM chlorite and pH-corrected = NP001, aka WF10) was developed to mimic this effect."

****!!!!***

The invention relates to a pharmaceutical composition for the parenteral treatment of infectious diseases, based on an aqueous, sterile and pyrogen-free solution of chlorine dioxide, the 5 to 1000 mg / l (ppm) of dissolved chlorine dioxide (CIO2) and 3 to 10 g / l of a ionic tonicity regulator, optionally in combination with a non-ionic tonicity regulator. The composition preferably also contains a pH regulator, in particular a pH buffer system adjusted to pH 7.3-7.5, and may further *****contain DMSO or MSM. The composition is free from chlorate ions, hydrochloric acid and gaseous chlorine in t... "Above all, the advantage of a high-purity CDL is that the possibility of any undesirable effects, which are described for Na-chlorite and above all for Na-chlorate in the specialist literature, is reduced even further, which is especially true for formulations and compositions is of particular importance, which should be used as infusion solutions or injection solutions. A composition according to the invention which, in addition to external, topical application, should be suitable above all for systemic, parenteral applications in the form of injection or infusion solutions,"

{Somewhat similar to TCDO} 2013. "Off-label use of sodium chlorite by patients with ALS (PALS) has received much recent attention in the lay press (1−3). Here, on behalf of PALS who requested it we review the evidence for sodium chlorite in ALS."